IQVIA Holdings (NYSE: IQV) reported Q3 EPS of $1.42, $0.03 better than the analyst estimate of $1.39. Revenue for the quarter came in at $2.59 billion.

• Revenue $2,594 million, up 6.3 percent at constant currency and 5.2 percent reported
• Adjusted EBITDA $561 million, up 8.4 percent at constant currency and 9.4 percent reported
• GAAP Diluted Earnings per Share $0.29
• Adjusted Diluted Earnings per Share $1.42, up 19.3 percent
• $792 million of share repurchase completed year-to-date; $133 million during the third quarter
• Record quarter of R&D Solutions contracted services Net New Business, resulting in a book-to-bill ratio of 1.69x
• Reaffirming mid-point of full-year 2018 revenue guidance inclusive of foreign currency headwind; raising mid-point of full-year 2018 Adjusted EBITDA and Adjusted Diluted EPS guidance

“We delivered another quarter of strong financial performance, with solid core growth in our R&DS and TAS segments,” said Ari Bousbib, chairman and CEO of IQVIA. “In R&DS, we had a record quarter of contracted services net new business, which positions us well to deliver on our merger synergy targets exiting 2019. Our technology business continues its strong momentum, driven by deals such as the recent milestone agreement with Roche to deploy and use IQVIA commercial technologies globally, and by the launch of our clinical technologies suite, which we are developing on Salesforce.”

GUIDANCE:

IQVIA Holdings sees FY2018 EPS of $5.45-$5.55, versus the consensus of $5.50. IQVIA Holdings sees FY2018 revenue of $10.3-10.35 billion, versus the consensus of $10.37 billion.

For earnings history and earnings-related data on IQVIA Holdings (IQV) click here.